Teva Pharmaceutical Industries Limited Q3 Earnings Fall 26%

Teva Pharmaceutical Industries Limited Q3 Earnings Fall 26%

Meanwhile, the generics segment could remain under pressure due to pricing erosion as well as the absence of important new product launches. Estimates have been going down ahead of the company's Q3 earnings release.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Analysts had modeled 63 cents on $1.325 billion, respectively.

Heading into the stock price potential, Teva Pharmaceutical Industries Limited needs to grow just 35.52% to cross its median price target of $19. Deutsche Bank AG reissued a buy rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has an average rating of Hold and an average target price of $27.83.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. 2,366,078 shares of the company's stock were exchanged. The stock has a beta value of 0.55. Moving toward the technical facts, its current distance from 20-Day Simple Moving Average is -5.35% and standing -13.03% away from 50-Day Simple Moving Average while traded down -48.67% from 200-Day Simple Moving Average. The Firm has ATR of 0.62 that is explaining range of a day's trading is high-low; ATR expands it to yesterday's closing price.

Teva Pharmaceutical (TEVA) missed third-quarter earnings estimates and gave weak full-year guidance early Thursday, while animal drug specialist Zoetis (ZTS) topped quarterly profit and sales forecasts.

Teva in August said it had taken a $6.1 billion write-down on its US generics unit to reflect dimming prospects, dragging the company's quarterly net loss down to $6.04 billion. The company's revenue for the quarter was up 12.9% on a year-over-year basis. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. This was lower than $1.36 billion, or $1.31 per share, in last year's third quarter.

The Israeli drugmaker cut its earnings per share estimate for the year Thursday as it predicted weaker revenue from its US generics business.

A number of hedge funds have recently added to or reduced their stakes in TEVA. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited during the 3rd quarter worth about $129,000. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter valued at about $106,000. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company's stock worth $123,000 after buying an additional 94 shares during the period.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. Financial Counselors Inc. now owns 140,599 shares of the company's stock worth $4,671,000 after acquiring an additional 7,571 shares during the last quarter.

Teva Pharmaceutical Industries Limited is a global pharmaceutical company.

Related Articles